We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Investigator Protocol Agreement Sample Contracts

INVESTIGATOR PROTOCOL AGREEMENT PAGE
Investigator Protocol Agreement • May 22nd, 2019

This study will not commence without the prior written approval of a properly constituted Institutional Review Board (IRB). No changes will be made to the study protocol without the prior written approval of the sponsor and the IRB, except where necessary to eliminate an immediate hazard to the patient.

Standard Contracts

INVESTIGATOR PROTOCOL AGREEMENT PAGE
Investigator Protocol Agreement • November 10th, 2024
INVESTIGATOR PROTOCOL AGREEMENT
Investigator Protocol Agreement • May 24th, 2022

Title: A SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda®) with vitamin D receptor agonist Paricalcitol (Zemplar®) in Patients with Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (with no further improvement in their tumor)

SIGNATURE PAGE
Investigator Protocol Agreement • July 29th, 2021
INVESTIGATOR PROTOCOL AGREEMENT PAGE
Investigator Protocol Agreement • September 20th, 2022
INVESTIGATOR PROTOCOL AGREEMENT PAGE
Investigator Protocol Agreement • April 12th, 2015

This study will not commence without the prior written approval of a properly constituted Institutional Review Board (IRB). No changes will be made to the study protocol without the prior written approval of the sponsor and the IRB, except where necessary to eliminate an immediate hazard to the patient.

INVESTIGTOR PROTOCOL AGREEMENT PAGE
Investigator Protocol Agreement • February 19th, 2018

• To assume responsibility for the proper conduct of the study at this site and supervise all testing of the device involving human subjects